JP7850665B2 - 血管脂肪腫の処置のための組成物 - Google Patents

血管脂肪腫の処置のための組成物

Info

Publication number
JP7850665B2
JP7850665B2 JP2022542777A JP2022542777A JP7850665B2 JP 7850665 B2 JP7850665 B2 JP 7850665B2 JP 2022542777 A JP2022542777 A JP 2022542777A JP 2022542777 A JP2022542777 A JP 2022542777A JP 7850665 B2 JP7850665 B2 JP 7850665B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
angiolipoma
weight
acid
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510865A (ja
JP2023510865A5 (https=
Inventor
ブルメンフェルド，アロン
ゲータ，ラケーリ
ブローグランド，エラン
Original Assignee
ラジエル セラピューティクス エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラジエル セラピューティクス エルティーディー． filed Critical ラジエル セラピューティクス エルティーディー．
Publication of JP2023510865A publication Critical patent/JP2023510865A/ja
Publication of JP2023510865A5 publication Critical patent/JP2023510865A5/ja
Application granted granted Critical
Publication of JP7850665B2 publication Critical patent/JP7850665B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
JP2022542777A 2020-01-28 2021-01-27 血管脂肪腫の処置のための組成物 Active JP7850665B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062966577P 2020-01-28 2020-01-28
US62/966,577 2020-01-28
PCT/IB2021/000035 WO2021152390A1 (en) 2020-01-28 2021-01-27 Compositions for the treatment of angiolipoma

Publications (3)

Publication Number Publication Date
JP2023510865A JP2023510865A (ja) 2023-03-15
JP2023510865A5 JP2023510865A5 (https=) 2023-12-13
JP7850665B2 true JP7850665B2 (ja) 2026-04-23

Family

ID=77078612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542777A Active JP7850665B2 (ja) 2020-01-28 2021-01-27 血管脂肪腫の処置のための組成物

Country Status (7)

Country Link
US (1) US20230089484A1 (https=)
EP (1) EP4096653A4 (https=)
JP (1) JP7850665B2 (https=)
CN (1) CN115335047B (https=)
AU (1) AU2021213469A1 (https=)
IL (1) IL295014A (https=)
WO (1) WO2021152390A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307323B1 (en) 2015-06-15 2022-07-13 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
AU2020347539A1 (en) * 2019-09-15 2022-03-31 Raziel Therapeutics Ltd. Compositions for the treatment of solid tumors
JP2024529906A (ja) * 2021-07-28 2024-08-14 ラジエル セラピューティクス エルティーディー． 脂肪腫の疼痛を処置するための組成物および方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533264A (ja) 2011-11-15 2014-12-11 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド 三環式化合物、それらを含む組成物およびそれらの使用
WO2015061280A1 (en) 2013-10-21 2015-04-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016020919A1 (en) 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102712601A (zh) * 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
RU2020111934A (ru) * 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533264A (ja) 2011-11-15 2014-12-11 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド 三環式化合物、それらを含む組成物およびそれらの使用
WO2015061280A1 (en) 2013-10-21 2015-04-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016020919A1 (en) 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RZL-012 for Dercum's Disease Lipomas，ClinicalTrials.gov，2020年01月14日，https://clinicaltrials.gov/study/NCT04229030?tab=history&a=1#version-content-panel, [オンライン],[検索日 2024.11.14]，NCT04229030
Sonographic Differentiation Between Angiolipomas and Superficial Lipomas，JOURNAL OF ULTRASOUND IN MEDICINE，2016年，35(11)，0pp.2421-2429，doi:10.7863/ultra.15.08050
Successful treatment with interferon alfa in infiltrating angiolipoma: a case presenting with Kasabach-Merritt syndrome，Arch Dis Child，88(1)，2003年，pp.67-68

Also Published As

Publication number Publication date
IL295014A (en) 2022-09-01
EP4096653A4 (en) 2024-02-28
EP4096653A1 (en) 2022-12-07
WO2021152390A1 (en) 2021-08-05
US20230089484A1 (en) 2023-03-23
JP2023510865A (ja) 2023-03-15
CN115335047B (zh) 2025-09-19
CN115335047A (zh) 2022-11-11
AU2021213469A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
JP7850665B2 (ja) 血管脂肪腫の処置のための組成物
JP2021519282A (ja) ＨＩＦ−２−αの阻害薬による消化器系の炎症軽減方法
JP7822308B2 (ja) 固形腫瘍の処置のための組成物
KR19980081621A (ko) 과민성 장 증후군의 증상을 치료하기 위한 엔케이-1 수용체 길항물질
TW202432558A (zh) 一種噠嗪稠芳環化合物及其用途
CA3157869A1 (en) Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment
EP4149941B1 (en) Certain chemical compositions and methods of use thereof
US20230355584A1 (en) Compositions and methods for the treatment of lipid-related disorders
WO2022058792A1 (en) Compositions for the treatment of fat related conditions and disorders
US4851414A (en) Anti-dementia agent
JP2024529906A (ja) 脂肪腫の疼痛を処置するための組成物および方法
HK40077772A (en) Compositions for the treatment of solid tumors
JP2008214252A (ja) プロテインホスファターゼ２ｃ活性化剤
US20200289593A1 (en) Spirulina carotenoid complex
WO1992003134A1 (en) New pharmaceutical formulations of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole
JPH04208264A (ja) 新規アルカロイドおよび該アルカロイドを有効成分とするグルコシダーゼ阻害剤
JPH04202128A (ja) 肝障害治療薬
JPH04202129A (ja) 肝障害治療薬
JPH1129478A (ja) ジヒドロキノリン誘導体を含有する医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260413

R150 Certificate of patent or registration of utility model

Ref document number: 7850665

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150